Evogene is now focusing on finding new drugs for acute graft-versus-host disease using its AI program.

EVGN · Evogene Ltd.

The AI's read

Evogene now has a concrete set of candidates aimed at a disease with limited treatment choices. The candidates are still being developed, and the announcement gives no results in people. The progress supports a positive read, but it does not show that the candidates will become a treatment.